Population pharmacokinetics is the study of the sources and correlates of variability in drug concentrations among individuals who are the target patient population receiving clinically relevant doses. Unlike traditional pharmacokinetic studies that intensively sample a small number of healthy volunteers, population pharmacokinetics analyzes sparse concentration data collected from a large number of patients under routine clinical conditions. This approach quantifies both typical pharmacokinetic behavior and the interindividual and intraindividual variability around the typical values.
NONMEM Methodology
The standard analytical tool for population pharmacokinetic analysis is NONMEM (Nonlinear Mixed Effects Modeling) , developed at the University of California, San Francisco. NONMEM implements a nonlinear mixed-effects modeling approach that simultaneously estimates fixed effects and random effects. Fixed effects are the typical population parameters: clearance, volume of distribution, absorption rate constant, and the influence of covariates such as weight, age, or renal function on these parameters. Random effects quantify the variability that remains unexplained after accounting for fixed effects.
The random effects are divided into interindividual variability (IIV) , representing differences between subjects in pharmacokinetic parameters, and residual variability, representing the difference between the model-predicted and observed concentrations within an individual. Residual variability includes measurement error, model misspecification, and intraindividual variability over time. By partitioning variability into these components, population pharmacokinetic analysis provides a comprehensive description of drug disposition across the target population.
Fixed and Random Effects
The structural model in population pharmacokinetics defines the typical pharmacokinetic profile using compartmental equations. For example, a one-compartment model with first-order elimination describes the typical clearance and volume of distribution. The random effects model then describes how individual parameters deviate from the typical values. Interindividual variability is typically modeled using an exponential error model: the individual parameter equals the typical parameter multiplied by e to the power of eta, where eta is assumed to be normally distributed with a mean of zero and a variance omega squared.
Covariates are incorporated into the fixed effects model to explain interindividual variability. Common covariates include weight, age, sex, serum creatinine or creatinine clearance for renally eliminated drugs, and measures of hepatic function for hepatically cleared drugs. The covariate model may use linear or nonlinear relationships, such as allometric scaling of clearance by weight raised to the 0.75 power. The addition of covariates should improve model fit sufficiently to justify the increased complexity.
Study Design Considerations
Population pharmacokinetic studies typically use sparse sampling, where each patient contributes only a few concentration measurements. This design is practical for routine clinical care and allows inclusion of patient populations that are difficult to study in traditional designs, such as critically ill patients, neonates, or elderly patients with multiple comorbidities. The optimal sampling design for population studies seeks to collect samples at informative times across the dosing interval from different patients, a concept known as optimal design.
The number of subjects in a population pharmacokinetic study is typically larger than in traditional studies, with 50 to several hundred subjects being common. The actual number depends on the complexity of the model, the expected variability, and the number of covariates to be evaluated. Simulation-based approaches are used during the design phase to determine the sample size needed to estimate parameters with adequate precision.
Interindividual and Intraindividual Variability
Understanding the magnitude of interindividual variability is critical for determining whether a fixed dosing regimen is adequate or whether individualized dosing is necessary. For a drug with low interindividual variability, a standard dose produces similar concentrations in most patients. For a drug with high interindividual variability, patients receiving the same dose may have widely different concentrations, and dose individualization based on patient characteristics or therapeutic drug monitoring is warranted.
Intraindividual variability describes changes in an individual’s pharmacokinetics over time, which may result from disease progression, drug interactions, or changes in physiological status. Quantifying intraindividual variability helps determine the frequency of monitoring needed and the reliability of a single concentration measurement for predicting future concentrations.
Applications in Special Populations
Population pharmacokinetic analysis is particularly valuable for studying drug disposition in special populations that are underrepresented in traditional clinical trials. Pediatric population pharmacokinetic studies have characterized the maturation of drug-metabolizing enzymes and renal function, enabling evidence-based dose recommendations for children of different ages. Geriatric studies have quantified the impact of age-related physiological changes on drug clearance. Studies in patients with renal or hepatic impairment have provided the pharmacokinetic basis for dose adjustment recommendations.
The approach is also used to evaluate the effects of genetic polymorphisms on drug disposition. By including genotype as a covariate in the population model, the impact of CYP2D6, CYP2C9, CYP2C19, and other polymorphic enzymes on drug clearance can be quantified, supporting genotype-guided dosing strategies.
Bayesian Estimation in Practice
Population pharmacokinetic models serve as the basis for Bayesian estimation in therapeutic drug monitoring. The population model provides prior information about the typical parameter values and their variability, which is updated with the patient’s own concentration measurements to obtain individualized parameter estimates. This Bayesian approach allows precise dose individualization even with sparse sampling, making it feasible to optimize therapy in routine clinical practice.
The integration of population pharmacokinetic principles with Bayesian feedback has transformed the management of drugs such as vancomycin and aminoglycosides, enabling clinicians to achieve target concentrations more rapidly and maintain them more consistently than with traditional dosing approaches. As computational tools become more accessible, population pharmacokinetic-guided dosing is expanding to a broader range of drugs.
